NCT00750256已完成1 期
A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- GSK1278863A safety endpoints: adverse events reporting, clinical safety laboratory tests (hematology, chemistry, urinalysis,and fecal occult blood), vital signs, 12-lead ECG, dual-lead cardiac monitoring.
研究概览
简要总结
A first-time in human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1278863A in healthy subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, non-smoking (within 40 days of screening), adult males and females between 18 and 55 years of age, inclusive
- •Female subjects are eligible for participation in the study if they are of:
- •Non-childbearing potential (i.e., physiologically incapable of becoming pregnant);
- •Male subjects agree to use contraception methods
- •Body weight > or = 50 kg; BMI: 19-31 kg/m2, inclusive
- •Subject has a QTc <450 msec or <480 msec if associated with bundle branch block
- •Subject is willing and able to provide written informed consent
排除标准
- •MCV value outside the reference range at screening
- •Hemoglobin value at screening is: male subjects or post-menopausal females > 15.5 g/dL; female subjects > 14.5 g/dL
- •TIBC, serum iron and serum ferritin values are outside the reference range at screening
- •Calculated creatinine clearance < 60 ml/min
- •Clinically significant abnormal CPK determined by the investigator and medical monitor
- •AST, ALT and direct bilirubin are greater than upper limit of reference range at screening
- •Subjects are unwilling or inability to follow the procedures and lifestyle and/or dietary restrictions outlined in the protocol
- •Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor this will not interfere with the study procedures or compromise subject safety
- •Subject currently exposures to more than four new chemical entities within 12 months prior to the first dosing day
- •Use of other prescription or non-prescription drugs, vitamins, herbal and dietary supplements, within 7 days prior to the first dose of study medication
- •Subject has a history of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy
- •Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs.
- •Subject has a history of GI ulceration or gastrointestinal bleeding
- •Subject has a history of peptic ulcer disease
- •Subject has a history of malignancy tumor; non-melanoma skin cancer that has been definitely removed is allowed
- •Treatment with an investigational drug within 30 days preceding the first dose of study medication
- •Subjects with a history of drug abuse
- •History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening
- •Positive urine drug screen (UDS) at screening
- •Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result or positive HIV result within 3 months of screening
- •Donation of blood in excess of 500 mL within 56 days prior to first dose of study medication
- •Subject has a history of regular use of tobacco- or nicotine containing products
- •History of sensitivity to heparin, heparin-induced thrombocytopenia or sensitivity to any of the study medications or components thereof
研究组 & 干预措施
Cohorts
Experimental
This study will be a single-blind, randomized, placebo-controlled, dose-rising, single dose, parallel group study with 6 proposed Cohorts from 2mg to 450mg.
干预措施: GSK1278863A (Drug)
结局指标
主要结局
GSK1278863A safety endpoints: adverse events reporting, clinical safety laboratory tests (hematology, chemistry, urinalysis,and fecal occult blood), vital signs, 12-lead ECG, dual-lead cardiac monitoring.
时间窗: 1 Day
次要结局
- Blood and urine levels of GSK1278863A(2 Days)
- Effect of GSK1278863A on hematological markers(2 Days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult VolunteersVenous ThromboembolismNCT03919890Ono Pharmaceutical Co. Ltd72
已完成
1 期
A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy ParticipantsAlzheimer's DiseaseNCT04476303BeyondBio Inc.88
招募中
1 期
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy SubjectsIgA NephropathyFocal Segmental GlomerulosclerosisNCT05942625Hansoh BioMedical R&D Company84
已完成
1 期
A First-in-Human Single and Multiple Ascending Dose Study of MT-501Healthy VolunteersNCT06762457Mirador Therapeutics, Inc.72
终止
1 期
A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male SubjectsCardiovascular DiseaseNCT02712372AstraZeneca104